Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 1
2011 1
2012 3
2013 1
2014 2
2015 1
2016 5
2017 1
2019 1
2020 1
2021 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults.
Pierson W, Tuefferd M, Herschke F, Slaets L, Crabbe M, Verstappen D, De Pelsmaeker S, Strickland I, Gane EJ, Schwabe C, Zhang Y, Meerts P, Vandenbossche J, Van Remoortere P, Verbrugge I, De Creus A. Pierson W, et al. Among authors: verbrugge i. Antivir Ther. 2023 Jun;28(3):13596535231172878. doi: 10.1177/13596535231172878. Antivir Ther. 2023. PMID: 37199270 Free article.
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants.
Wu LS, Hu Y, Gane EJ, Slaets L, De Creus A, Ding Y, Niu J, Schwabe C, Goeyvaerts N, Xu Z, Huo D, Tuefferd M, Verbrugge I, Van Remoortere P, Schwertschlag U, Vandenbossche J. Wu LS, et al. Among authors: verbrugge i. Antivir Ther. 2023 Feb;28(1):13596535231151626. doi: 10.1177/13596535231151626. Antivir Ther. 2023. PMID: 36691849 Free article.
Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells.
Matas-Rico E, Frijlink E, van der Haar Àvila I, Menegakis A, van Zon M, Morris AJ, Koster J, Salgado-Polo F, de Kivit S, Lança T, Mazzocca A, Johnson Z, Haanen J, Schumacher TN, Perrakis A, Verbrugge I, van den Berg JH, Borst J, Moolenaar WH. Matas-Rico E, et al. Among authors: verbrugge i. Cell Rep. 2021 Nov 16;37(7):110013. doi: 10.1016/j.celrep.2021.110013. Cell Rep. 2021. PMID: 34788605 Free PMC article.
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, Wall M, Pavy M, Cullinane C, Diesch J, Devlin JR, George AJ, Sanij E, Quin J, Poortinga G, Verbrugge I, Baker A, Drygin D, Harrison SJ, Rozario JD, Powell JA, Pitson SM, Zuber J, Johnstone RW, Dawson MA, Guthridge MA, Wei A, McArthur GA, Pearson RB, Hannan RD. Hein N, et al. Among authors: verbrugge i. Blood. 2017 May 25;129(21):2882-2895. doi: 10.1182/blood-2016-05-718171. Epub 2017 Mar 10. Blood. 2017. PMID: 28283481 Free PMC article.
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen JB, Long GV, Blank CU. Deken MA, et al. Among authors: verbrugge i. Oncoimmunology. 2016 Oct 14;5(12):e1238557. doi: 10.1080/2162402X.2016.1238557. eCollection 2016. Oncoimmunology. 2016. PMID: 28123875 Free PMC article.
22 results